Suzhou Vigonvita Biomedical

Vigonvita Life Sciences is a commercial-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery, development, and commercialization of innovative small-molecule drugs. Founded in 2013 as an incubation enterprise of the Shanghai Institute of Materia Medica, the company focuses on three strategic therapeutic areas: viral infections, neuropsychiatry, and reproductive health. Its commercial portfolio includes VV116 (deuremidevir hydrobromide), an oral nucleoside antiviral approved for COVID-19, and TPN171 (simenafil hydrochloride), a potent PDE5 inhibitor approved for erectile dysfunction. Vigonvita operates a fully integrated platform with end-to-end capabilities, including R&D centers in Suzhou and Shanghai and a GMP-compliant manufacturing facility in Lianyungang. The company is listed on the Hong Kong Stock Exchange (HKEX: 2630) and maintains a robust pipeline targeting indications such as respiratory syncytial virus (RSV), major depressive disorder, and epilepsy.